Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-7246. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 16/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 12/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-7246 SCHEMBL233950 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| Mk-7246 SCHEMBL2186905 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| Mk-7246 SCHEMBL15428834 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347583 | 0.90 | PTGDR2 (0.82) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347569 | 0.90 | PTGDR2 (0.82) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL13137620 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL232733 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12355439 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL12347578 | 0.87 | PTGDR2 (0.77) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 | |
| SCHEMBL1770880 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192765-A1 | FIRST IN CLASS USE OF THE CRTH2 ANTAGONIST IN TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND RELEVANT AUTOIMMUNE CNS DISORDERS | BROWN UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-17 | — | — | US | disclosed |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024192765-A1 | FIRST IN CLASS USE OF THE CRTH2 ANTAGONIST IN TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND RELEVANT AUTOIMMUNE CNS DISORDERS | BROWN UNIVERSITY (US) | 2024-09-26 | — | — | WO | disclosed |
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240002376-A1 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | KANDEEL, FOUAD | 2024-01-04 | — | — | US | disclosed |
| EP-3565635-B1 | METHODS FOR DIAGNOSING ASTHMA AND COMPOSITIONS FOR USE IN TARGETING THE TH2 PATHWAY IN THE TREATMENT OF ASTHMA | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230159659-A1 | INHIBITION OF CYSTATINS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-05-25 | — | — | US | disclosed |
| EP-3328500-B1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916257-A | PGD 2 DPr2 and thromboxane A 2 Dual antagonists of the TPr receptor and their use for the treatment of adaptive immune responses or thrombotic conditions | 应用医疗技术有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11583517-B2 | Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis | APPLIED MEDICAL TECHNOLOGIES LLC (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126050-A1 | DUAL ANTAGONIST OF PGD2/DPR2 AND THROMBOXANE A2/TPR RECEPTORS AND USE FOR TREATMENT OF MALAPTIVE IMMUNE RESPONSE OR THROMBOTIC DIATHESIS | Applied Medical Technologies LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220184031-A1 | DUAL ANTAGONIST OF PGD2/DPR2 AND THROMBOXANE A2/TPR RECEPTORS AND USE FOR TREATMENT OF MALADAPTIVE IMMUNE RESPONSE OR THROMBOTIC DIATHESIS | APPLIED MEDICAL TECHNOLOGIES LLC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220176094-A1 | NEEDLING DEVICE AND DRUG APPLICATOR | FOLLICA INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-111233716-B | Preparation method of nickel-catalyzed alpha-deuterated chiral sulfonamide compound | 山东师范大学 | 2022-04-15 | — | — | CN | disclosed |
| EP-3981337-A1 | NEEDLING DEVICE | Follica, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022046605-A1 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | CITY OF HOPE (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885PTGDR 6/4885TBXA2R 1003/4885 |
| US-20240002376-A1 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | GPR4, GPR68, GPR27 | PTGDR2 174/4885PTGDR 126/4885TBXA2R 226/4885 |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885PTGDR 6/4885TBXA2R 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.